Alexion Pharmaceuticals
American company
Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in New Haven, Connecticut, specializing in orphan drugs for rare diseases.
Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq), used to treat hypophosphatasia; sebelipase alfa (Kanuma), used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa), used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.
With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide.
History
Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell, a physician at Yale New Haven Hospital and assistant professor of medicine and pathology at Yale School of Medicine.
In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut.
Alexion received U.S. Food and Drug Administration (FDA) approval for Soliris in 2007. It was initially approved to treat paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
In June 2010, there was an outbreak of hemolytic–uremic syndrome caused by shigatoxigenic and verotoxigenic Escherichia coli (EHEC) in Germany. Soliris was tested as a treatment option because of its effectiveness in treating atypical hemolytic uremic syndrome, an illness similar to that caused by the EHEC infection.
In January 2014, the company paid Moderna $100 million for ten product options to develop rare disease treatments, including for Crigler–Najjar syndrome, using Moderna's mRNA therapeutics platform; however, the program was scrapped in January 2017 after animal trials showed that Moderna's treatment would never be safe enough for humans.
The public source identifies “Alexion Pharmaceuticals” as american company. This brief keeps that definition visible, then builds a research path around Alexion, Pharmaceuticals and American.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Alexion Pharmaceuticals”, the useful work is to connect “american company” to the records capable of establishing context and consequence.
The record creator and administrative purpose are central evidence, because official documentation reflects both action and institutional priorities. The source revision retrieved here is dated Sep 9, 2026. The linked authority identifier is Q204727. 2 of 4 selected statements include explicit references; 1 carry qualifiers and 0 use preferred rank. The first chronological checks are 1992, 2000, 2007 and 2010.
Institutional narratives can privilege the records that survived while minimizing voices that were never formally collected. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Compare institutional narratives with records created by participants and affected communities. Dates and formal titles are useful anchors, but not substitutes for context.
- Event chronology
- Institutional context
- Locating named record creators
Contemporary correspondence, government or organizational records, oral histories and cited historical scholarship.
Three-step research path
- Establish the record: confirm the title “Alexion Pharmaceuticals”, its source revision and the description used here.
- Expand the search: follow Alexion Pharmaceuticals primary sources, Alexion Pharmaceuticals archive and Alexion research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Alexion Pharmaceuticals”?
- Who created the surviving record, and for what administrative purpose?
- What chronology connects this entry to wider political or social change?
Search terms from this dossier
This entry incorporates text from “Alexion Pharmaceuticals” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.